Scientific Advisory Board

Silo Pharma

Focused on merging traditional therapeutics with psychedelic research to innovatively address underserved conditions including Fibromyalgia, PTSD, Alzheimer's, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry.

Company

Home
Team
Advisory Board
Contact Us

Drug Pipeline

SPC-14
SPC-15
SP-26
SPU-16

Investors

Stock Information
SEC Filings
Board of Directors
Latest News
Email Alerts

Terms & Conditions Privacy Policy

Corporate Governance

Reports Regarding LMP Automotive Holdings’ Accounting or Auditing Matters or Other Concerns and Communications with the Board of Directors.

Shareholders and interested parties may communicate directly with the Board of Directors, the Audit Committee of the Board of Directors with respect to accounting issues, questionable accounting or auditing matters or internal accounting controls, any other Board committee, any individual Director, any group of Directors or the Lead Independent Director by e-mailing businessethics@lmpah.com.

Reports may be made anonymously or confidentially.

Disclaimer

You are about to review presentations, reports and/or filings of Silo Pharma, Inc. , that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Silo Pharma, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Silo Pharma, Inc.

I Accept I Decline